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a-Synuclein is a synaptic modulatory protein implicated in the
pathogenesis of Parkinson disease. The precise functions of this
small cytosolic protein are still under investigation. a-Synuclein
has been proposed to regulate soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE) proteins involved in
vesicle fusion. Interestingly, a-synuclein fails to interact with
SNARE proteins in conventional protein-binding assays, thus
suggesting an indirect mode of action. As the structural and
functional properties of both a-synuclein and the SNARE proteins
can be modified by arachidonic acid, a common lipid regulator,
we analysed this possible tripartite link in detail. Here, we show
that the ability of arachidonic acid to stimulate SNARE complex
formation and exocytosis can be controlled by a-synuclein, both
in vitro and in vivo. a-Synuclein sequesters arachidonic acid and
thereby blocks the activation of SNAREs. Our data provide
mechanistic insights into the action of a-synuclein in the
modulation of neurotransmission.
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INTRODUCTION
a-Synuclein is a cytosolic protein that is enriched in mature nerve
terminals and has recently been implicated in the aetiology of
Parkinson disease (Spillantini et al, 1997; Cookson, 2009). The
physiological function of this abundant brain protein is not
yet fully defined. Several studies have indicated a role for
a-synuclein in the regulation of intracellular transport (Cooper
et al, 2006; Ben Gedalya et al, 2009; Sousa et al, 2009), including
synaptic vesicle fusion underlying neurotransmitter release
(Abeliovich et al, 2000; Murphy et al, 2000; Cabin et al, 2002;
Yavich et al, 2004; Nemani et al, 2010). Recently, a-synuclein
was shown to interfere with a late step in exocytosis (Larsen et al,
2006). The discovery of the soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE) proteins forming a
ternary complex that drives exocytosis (Sollner et al, 1993) allows
a detailed characterization of the mechanistic aspects of the
regulatory mechanisms that underlie vesicle fusion. We now
know that in the brain, at the neuromuscular junction and in the
endocrine organs, a set of three SNARE proteins has a main role
in accomplishing fusion of vesicular and plasma membranes.
These are syntaxin 1, synaptosomal-associated protein of 25 kDa
(SNAP25) and synaptobrevin 2. It is generally accepted that these
three proteins, which normally reside on opposing membranes,
engage each other and form a tight SNARE complex. The
formation of this complex drives membrane fusion, leading to
the release of the vesicular cargo into the extracellular space.
Recent studies have highlighted the lipid-based mechanisms
underlying various aspects of vesicle fusion and retrieval (Wenk
& De Camilli, 2004; Rigoni et al, 2005; Lang et al, 2008; Bader &
Vitale, 2009). It is widely recognized that arachidonic acid,
released from phospholipid membranes after the action of
phospholipases, and its metabolites are intimately involved in
the regulation of synaptic transmission (Kreitzer & Regehr, 2002;
Bazan, 2005). We showed recently that arachidonic acid
upregulates syntaxin and enhances its engagement with the
fusogenic SNARE complex (Rickman & Davletov, 2005; Connell
et al, 2007). Remarkably, the function of a-synuclein is also linked
to fatty acid metabolism (Perrin et al, 2001; Sharon et al, 2001;
Kubo et al, 2005; Broersen et al, 2006; Golovko et al, 2006).
These observations raise the possibility that the proposed effect of
a-synuclein on SNARE-mediated exocytosis might be explained
by an arachidonic acid link. Here, we investigated the mechanism
of the function of a-synuclein in SNARE assembly in the pres-
ence and absence of arachidonic acid. Our results show that
a-synuclein efficiently blocks arachidonic-acid-induced SNARE
interactions, both in vitro and in vivo, suggesting a physiological
role for a-synuclein.
RESULTS AND DISCUSSION
Effects of a-synuclein on SNARE assembly
First, we analysed the effect of a-synuclein on the formation of
the SNARE complex in the presence of arachidonic acid. The
defining property of the SNARE complex is its resistance
to dissociation by chaotropic agents, which disrupt the three-
dimensional structure of macromolecules, and detergents such
as sodium dodecyl sulpate (SDS; Hu et al, 2002). When syntaxin 1
is mixed with SNAP25 and synaptobrevin 2 for 20min, the
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SNARE complex can be detected directly by SDS–polyacrylamide
gel electrophoresis. Fig 1A shows that arachidonic acid enhanced
the formation of the SNARE complex, as reported previously
(Connell et al, 2007). The addition of a-synuclein in this reaction,
however, significantly reduced SNARE assembly, as was con-
firmed by gel band densitometry (Fig 1A). Further, kinetic
measurements showed that arachidonic acid accelerates the rate
of SNARE assembly, and a-synuclein blocks this accelerating
action (supplementary Fig S1 online). The addition of a-synuclein
resulted in a dose-dependent inhibition of SNARE complex
formation (Fig 1B). Furthermore, a-synuclein was effective at
all the concentrations of arachidonic acid tested, indicating
that the micromolar concentrations of this protein are sufficient
to reduce free fatty acid levels (Broersen et al, 2006) to the point at
which SNARE assembly would not be stimulated (Fig 1B). We also
investigated whether a-synuclein can alter SNARE assembly in
the absence of arachidonic acid. Interestingly, a-synuclein,
even at a high molar excess, did not modify SNARE complex
formation in such a scenario. Together, these results show that
a-synuclein requires the presence of arachidonic acid to modulate
SNARE assembly.
a-Synuclein inhibits fatty-acid-mediated exocytosis
To probe further the role of a-synuclein in SNARE regulation, we
investigated the effect of a-synuclein overexpression on vesicle
exocytosis in chromaffin cells. Chromaffin cells were transfected
using gold-particle-mediated gene transfer with vectors encoding
either a-synuclein or green fluorescent protein (GFP) as a control.
Transfected cells were identified by the presence of gold particles
and also by immunolocalization of a-synuclein or GFP (data not
shown). We monitored exocytosis in individual transfected cells
using the membrane dye FM1-43, which becomes fluorescent
when vesicles fuse with the plasma membrane after photorelease
of caged Ca2þ (Giner et al, 2007). The treatment of the cells with
arachidonic acid led to a significant increase in calcium-triggered
exocytosis in agreement with previous studies (Latham et al,
2007). When a similar experiment was repeated with a-synuclein-
overexpressing cells, the increase in exocytosis was largely
blocked, indicating that a-synuclein can efficiently control
arachidonic-acid-dependent functions (Fig 2A).
An earlier study showed that arachidonic acid specifically
activates the first step in the SNARE assembly pathway, that is, the
formation of the syntaxin–SNAP25 heterodimer (Connell et al,
Control AA α-Syn α-Syn+AA
0
20
40
60
S
N
A
R
E 
co
m
pl
ex
 
fo
rm
at
io
n 
(%
)
∗∗ ∗∗
A
B
15
20
25
37
50
75
kDa
Syb
α-Syn
SNAP25
Syx1
SNARE complex
1.7 3.5 7.0 140 α-Syn (μM)
0
20
40
0
3.5
7.0
14.0
50 100
S
N
A
R
E 
co
m
pl
ex
 
fo
rm
at
io
n 
(%
)
150
Arachidonic acid (μM)
AA
α-Syn
Time (min)0 20
− +−
−−
+ +
15
20
25
37
50
75
kDa
Syb
α-Syn
SNAP25
Syx1
SNARE complex
[α-Syn] (μM)
C
60
80
Fig 1 | a-Synuclein blocks arachidonic-acid-mediated SNARE assembly. (A) A Coomassie-stained gel (left) and a bar chart (right) showing an increase
in the amount of the ternary SNARE complex in the presence of arachidonic acid (100mM) in a 20-min reaction. This effect is blocked in the presence
of a-Syn (7 mM), Syx1, SNAP25 and Syb (1mM each). **Po0.01, n¼ 6. (B) Quantification of SNARE complex formation with different concentrations
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2007). To assess the role of a-synuclein in the formation of this
heterodimer in a cellular environment, we overexpressed the
protein in the pheochromocytoma cell line PC12. These cells
were transfected by electroporation, with more than 60% of the
cells expressing a-synuclein (data not shown), allowing bio-
chemical analysis. SNAP25 was immunoprecipitated and the
amount of bound syntaxin 1 was estimated by western immuno-
blotting. Fig 2B shows that arachidonic acid treatment enhanced
the interaction between syntaxin 1 and SNAP25, whereas over-
expression of a-synuclein efficiently blocked the accelerated
SNARE interaction in a cellular environment.
We noticed that the overexpressed a-synuclein did not interact
with cellular SNAP25 and syntaxin 1, as assessed by immuno-
precipitation (Fig 2B). To confirm that the action of a-synuclein
does not involve a direct interaction with any of the SNARE
proteins, we performed immunoprecipitation of a-synuclein
from purified synaptic endings (Rickman & Davletov, 2005;
Broersen et al, 2006). Fig 2C shows that endogenous a-synuclein
did not interact with the SNARE proteins in the presence or
absence of arachidonic acid (Fig 2C). These data suggest that
a-synuclein affects SNARE function without direct interaction with
the SNARE proteins, implying an interaction of a-synuclein with a
SNARE regulator, such as arachidonic acid.
a-Synuclein acts by sequestering arachidonic acid
We investigated whether previous exposure of arachidonic acid
solution to a-synuclein could still affect SNARE assembly. We
immobilized a-synuclein through a glutathione S-transferase tag
on Sepharose beads and incubated these beads with radioactive
arachidonic acid. Fig 3A shows that immobilized a-synuclein was
able to decrease free fatty acid concentration with an EC50 of
5 mM. Next we compared the effects of arachidonic acid solutions,
exposed or not to a-synuclein, on SNARE assembly. Fig 3B shows
that formation of the SNARE complex was downregulated when
the fatty acid was exposed to a-synuclein, confirming that this
protein can reduce free fatty acid levels to the point at which
SNARE assembly is not stimulated.
Among the three SNARE proteins, syntaxin is the most likely
target of arachidonic acid (Connell et al, 2007). We therefore
tested the effect of a-synuclein on the ability of syntaxin 1 to bind
to arachidonic acid by equilibrium dialysis. Syntaxin was placed
in the sample chamber, and, after equilibration with radioactively
labelled arachidonic acid, the distribution of the fatty acid was
estimated by scintillation counting. Fig 3C shows that arachidonic
acid was enriched in the syntaxin-containing chamber, indicating
that syntaxin bound to the fatty acid. Crucially, the addition of
a-synuclein to the equilibration buffer in the opposite chamber
prevented the binding of arachidonic acid to syntaxin (Fig 3C). As
the two proteins were physically separated in two compartments,
this result confirms that the inhibitory action of a-synuclein on
SNAREs is mediated by its sequestration of arachidonic acid.
It was important to test SNARE assembly properties in the
synaptic environment in which endogenous a-synuclein is highly
enriched (Clayton & George, 1999). First, we separated the rat
brain synaptic membranes, which contain the SNARE proteins,
from the synaptic cytosol, which is enriched in a-synuclein
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Fig 2 | a-Synuclein inhibits arachidonic-acid-induced exocytosis and SNARE interactions in neuroendocrine cells. (A) Representative curves (left) and a bar
chart (right) showing an increase in FM1-43 fluorescence following photorelease of caged Ca2þ in chromaffin cells, with or without a 30-min pretreatment
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chart (right) showing that AA (100mM) increases the amount of Syx1 immunoprecipitated with SNAP25 (IP) from PC12 neuroendocrine cells. This effect is
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(Fig 4A). Next, the cytosol was treated with a synuclein antibody
immobilized on Sepharose beads, which allowed nearly complete
removal of a-synuclein (Fig 4A; Broersen et al, 2006). Synaptic
membranes were then exposed to arachidonic acid and cytosol
preparations. The addition of arachidonic acid to synaptic
membranes in the presence of synuclein-depleted cytosol led to
a significant increase in the formation of the SNARE complex
(Fig 4B). However, when we used the original cytosol, containing
endogenous levels of a-synuclein, the effect of arachidonic acid
was downregulated (Fig 4B). We further tested the link between
the SNARE assembly and arachidonic acid in synaptic prepara-
tions obtained from mice lacking a-synuclein. The addition of
arachidonic acid to the synaptic membranes in the presence of the
synaptic cytosol taken from an a-synuclein/ mouse led to an
increase in SNARE assembly, whereas addition of the cytosol
obtained from mice carrying a-synuclein had a downregulating
effect (supplementary Fig S3 online). We conclude that endogen-
ous a-synuclein can control formation of the SNARE complex
mediated by arachidonic acid.
Finally, we analysed the effect of arachidonic acid on
glutamate release from isolated synaptic endings (synaptosomes)
obtained from the brain cortices of a-synuclein/ and control
mice (Fig 4C). For the measurement of glutamate release from
synaptosomes, we used a fluorescent microplate assay that relies
on the conversion of nicotinamide adenine dinucleotide
phosphate to its reduced form by glutamate dehydrogenase
(Darios et al, 2009). Consistent with recent studies of vesicle
exocytosis (Almeida et al, 1999; Rigoni et al, 2005; Latham et al,
2007; Nemani et al, 2010), the unsaturated fatty acid increased
glutamate release from the wild-type synaptic endings (Fig 4C).
However, this increase was evident, in the case of a-synuclein
ablation, at lower concentrations of arachidonic acid. Further-
more, the synaptic endings from a-synuclein/ mice showed
enhanced glutamate release even in the absence of exogenous
fatty acid (Fig 4C). Together, these data suggest that wild-type
nerve endings rely on a-synuclein to control the endogenous fatty
acid levels, which can be intimately involved in the regulation of
neurotransmitter release, for example, through syntaxin activation
(Connell et al, 2007).
Several recent studies have suggested a role for a-synuclein in
the regulation of vesicle transport and neurotransmitter release
(Abeliovich et al, 2000; Yavich et al, 2004; Sousa et al, 2009),
specifically affecting synaptic vesicle numbers or their clustering
(Murphy et al, 2000; Cabin et al, 2002; Nemani et al, 2010). It was
also proposed that a-synuclein inhibits neurotransmitter release, at
a late stage, between docking and fusion of synaptic vesicles,
possibly by affecting the function of the SNARE proteins (Chandra
et al, 2005; Larsen et al, 2006). Here, we investigated in detail the
relationship between a-synuclein and the SNARE proteins and
now show that a-synuclein can modulate SNARE properties
without direct binding. We show that a-synuclein can inhibit both
exocytosis and the formation of the SNARE complex by decreasing
the levels of free arachidonic acid available to the SNARE
proteins. Arachidonic acid, which can be released from cellular
membranes by the action of phospholipase A2 (Rossetto et al,
2006), is a well-characterized regulator of SNARE complex
formation and exocytosis in endocrine cells and neurons (Freeman
et al, 1990; Almeida et al, 1999; Connell et al, 2007; Latham et al,
2007). Our data show that endogenous cytosolic levels of
a-synuclein can buffer arachidonic acid and thereby affect
SNARE assembly, defining a possible physiological function for
a-synuclein. Together, our data highlight the protein–fatty acid
interaction that takes place in the regulation of SNARE-mediated
vesicular exocytosis, and suggest a role for a-synuclein in this
pathway. Interestingly, knockout of the a-synuclein gene produces
changes in the total mass of the polyunsaturated fatty acids
(Golovko et al, 2006) but results in only a mild phenotype,
suggesting that the free fatty acid–exocytosis relationship can be
modulated by other factors as well. It will now be important to
investigate how other synaptic components such as CSPa
(Chandra et al, 2005), Rab proteins (Cooper et al, 2006),
complexins (Melia, 2007), Munc18 (Rickman & Davletov, 2005)
and actin (Sousa et al, 2009) can contribute to or be influenced by
the a-synuclein–fatty acid link.
METHODS
Plasmids, antibodies and reagents. Plasmids encoding glu-
tathione S-transferase fusions of rat SNAP25, syntaxin 1 (amino
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acids 1–261), synaptobrevin 2 (amino acids 1–96) and human
a-synuclein have been described previously (Broersen et al, 2006;
Connell et al, 2007). Human a-synuclein complementary DNA
was subcloned into pcDNA3þ (Invitrogen) for expression in
mammalian cells. Mouse monoclonal antibodies against syntaxin 1
(clone HPC-1), SNAP25 (clone SMI81), synaptobrevin 2 (clone
69.1) and a-synuclein (clone 42) were from Sigma, Covance,
Synaptic Systems and BD Transduction Laboratories, respectively.
Rabbit anti-SNAP25 has been previously described (Bajohrs et al,
2005). Arachidonic acid was from Sigma. [3H]-Arachidonic acid
was from Perkin-Elmer.
Protein reactions and other experimental procedures. Isolation
of recombinant proteins has been described previously (Broersen
et al, 2006; Connell et al, 2007). All SNARE assembly reactions
were performed in 20mM HEPES, 100mM NaCl, pH 7.3, at
22 1C. Syntaxin 1 (1mM) and SNAP25 were preincubated with
a-synuclein and/or arachidonic acid for 5min. SNARE complex
formation was initiated by the addition of 1 mM synaptobrevin 2
and stopped, after 20min, by the addition of SDS-containing
sample buffer. The SNARE complex was visualized by Coomassie
staining of SDS–polyacrylamide gel electrophoresis gels. The
SNARE complex was quantified using the ChemiDoc XRS system
and Quantity One software (BioRad).
The isolation of synaptic fractions, cell culture, secretion
assay, immunoprecipitation, binding of arachidonic acid, SDS–
polyacrylamide gel electrophoresis, western immunoblotting and
statistical analyses are described in the supplementary information
online. a-Synuclein/ mice (C57BL/6S; Specht & Schoepfer,
2001) were obtained from Harlan, UK.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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